Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and etoposide

fulvestrant has been researched along with etoposide in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dive, C; Hickman, JA; Morris, ID; Wakeling, AE; Wilson, JW1
Obrero, M; Shapiro, DJ; Yu, DV1
Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM1

Reviews

1 review(s) available for fulvestrant and etoposide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for fulvestrant and etoposide

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage.
    International journal of cancer, 1995, May-16, Volume: 61, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Etoposide; Fulvestrant; Humans; Mechlorethamine; Neoplasms, Hormone-Dependent; Tumor Cells, Cultured

1995
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    The Journal of biological chemistry, 2002, Nov-22, Volume: 277, Issue:47

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Fractionation; Cell Size; Estradiol; Estrogen Antagonists; Etoposide; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Microscopy, Electron; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcriptional Activation

2002
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
    Cancer letters, 2014, Aug-01, Volume: 350, Issue:1-2

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53

2014